Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05161481 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT05161481 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 80 participants.
The verdict
NCT05161481, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this condition. Participants are put into 3 groups randomly, which means by chance. Participants in 2 groups take different doses of Avenciguat as tablets twice a day. Participants in the placebo group take placebo as tablets twice a day. Placebo tablets look like Avenciguat tablets but do not contain any medicine. Participants are in the study for about 8 months. During this time, they visit the study site about 14 times. At 3 of the visits, the doctors check the pressure in a liver vein. This is done with a catheter (a long thin tube) and gives information about the pressure in the portal vein. The change in blood pressure is then compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG Avenciguat (BI 685509)
- DRUG Placebo matching Avenciguat (BI 685509)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2024-06-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05161481
The ClinicalTrials.gov registry entry for NCT05161481 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avenciguat (BI 685509) is the first listed.
NCT05161481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05161481 about?
NCT05161481 is a clinical study titled "A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)". This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this condition. Participants are put into 3 groups randomly, which means by ...
What is the current status of trial NCT05161481?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2022-04-27. Estimated completion is 2024-06-12.
What interventions are being tested in trial NCT05161481?
The interventions under investigation include: Avenciguat (BI 685509) (DRUG), Placebo matching Avenciguat (BI 685509) (DRUG).
Who is sponsoring clinical trial NCT05161481?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.